Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), announced today that the
company will hold a conference call on Tuesday, May 27 at 8:30 a.m. ET
to discuss its alliance with Takeda announced this morning. Conference Call Information The call may be accessed by dialing 800-329-9097 (domestic) or
617-614-4929 (international) five minutes prior to the start time and
providing the passcode 36634290. A replay of the call will be available
from 2:00 p.m. ET May 27, 2008 until June 3, 2008. To access the replay
please dial 888-286-8010 (domestic) or 617-801-6888 (international) and
provide the passcode 90685470. A live audio webcast of the call will
also be available on the "Investors" section of the company´s website, www.alnylam.com.
An archived webcast will be available on the Alnylam website
approximately two hours after the event, and will be archived for 14
days thereafter. About Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutics
based on RNA interference, or RNAi. The company is applying its
therapeutic expertise in RNAi to address significant medical needs, many
of which cannot effectively be addressed with small molecules or
antibodies, the current major classes of drugs. Alnylam is leading the
translation of RNAi as a new class of innovative medicines with
peer-reviewed research efforts published in the world´s
top scientific journals including Nature, Nature Medicine
and Cell. The company is leveraging these capabilities to build a
broad pipeline of RNAi therapeutics; its most advanced program is in
Phase II human clinical trials for the treatment of respiratory
syncytial virus (RSV) infection. In addition, the company is developing
RNAi therapeutics for the treatment of a wide range of disease areas
including hypercholesterolemia, liver cancers, and Huntington´s
disease. The company´s leadership position in
fundamental patents, technology, and know-how relating to RNAi has
enabled it to form major alliances with leading companies including
Medtronic, Novartis, Biogen Idec, Roche, and Takeda. To reflect its
outlook for key scientific, clinical, and business initiatives, Alnylam
has established "RNAi 2010" which includes the company´s plan to
significantly expand the scope of delivery solutions for RNAi
therapeutics, have four or more programs in clinical development, and to
form four or more new major business collaborations, all by the end of
2010. Alnylam is a joint owner of Regulus Therapeutics LLC, a joint
venture focused on the discovery, development, and commercialization of
microRNA therapeutics. Founded in 2002, Alnylam maintains headquarters
in Cambridge, Massachusetts. For more information, visit www.alnylam.com.
